We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
Catalyst rich 2021 includes expected topline readouts from ten clinical trials across the Company’s depression, neurology and neuropsychiatry franchises and in COVID-related ARDS Company committed to accelerating pipeline and expanding product engine with goal of delivering at least two
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
Barry Greene , a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders Jeff Jonas to assume new role of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S. , excluding rights to zuranolone in Japan , Taiwan and South Korea Sage
Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020 Continued execution across brain health franchises highlighted during 2 nd annual FutureCast event First patient dosed in PARADIGM Study
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas , M.D.,
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
Zuranolone was generally well-tolerated at the 30 mg dose and by the initial patients treated with the 50 mg dose with an adverse event profile consistent with that seen in earlier trials Nearly half of trial participants with positive response to initial 14-day course of zuranolone 30 mg did not